US 11,655,277 B2
IL-12 heterodimeric Fc-fusion proteins
Matthew Bernett, Monrovia, CA (US); John R. Desjarlais, Pasadena, CA (US); Rajat Varma, Hamden, CT (US); Ke Liu, Glendora, CA (US); Nargess Hassanzadeh-Kiabi, Pasadena, CA (US); and Rumana Rashid, Temple City, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Aug. 11, 2022, as Appl. No. 17/886,103.
Application 17/886,103 is a continuation of application No. 17/718,087, filed on Apr. 11, 2022.
Application 17/718,087 is a continuation of application No. 16/592,656, filed on Oct. 3, 2019, granted, now 11,358,999, issued on Jun. 14, 2022.
Claims priority of provisional application 62/848,512, filed on May 15, 2019.
Claims priority of provisional application 62/810,038, filed on Feb. 25, 2019.
Claims priority of provisional application 62/740,813, filed on Oct. 3, 2018.
Prior Publication US 2023/0027540 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 47/68 (2017.01); C07K 14/54 (2006.01); C07K 19/00 (2006.01); C07K 1/18 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/5434 (2013.01) [A61K 47/6813 (2017.08); C07K 19/00 (2013.01); A61K 38/00 (2013.01); A61K 38/208 (2013.01); C07K 1/18 (2013.01); C07K 2319/30 (2013.01)] 1 Claim
 
1. A pharmaceutical composition comprising:
a) a heterodimeric Fc fusion protein comprising:
i) a first fusion protein comprising an amino acid sequence as set forth in SEQ ID NO: 382; and
ii) a second fusion protein comprising an amino acid sequence as set forth in SEQ ID NO: 404,
wherein said first fusion protein further comprises the amino acid substitutions M428L/N434S as compared to SEQ ID NO:382 and said second fusion protein further comprises the amino acid substitutions M428L/N434S as compared to SEQ ID NO:404, wherein the numbering of each amino acid substitution is according to EU numbering; and
b) a pharmaceutically acceptable carrier.